Intelligent Bio Solutions (Nasdaq: INBS) demonstrated financial progress in its fiscal third quarter of 2025, reporting a 20% sequential revenue increase to $728,867. The medical technology company's performance was primarily driven by robust cartridge sales, which now represent 58% of total revenue and are strengthening its recurring revenue model.
The company's gross profit surged 91% year-over-year to $341,368, while simultaneously reducing its net loss by $434,141 to $2.54 million. This financial improvement suggests the company is making strategic strides in operational efficiency and market penetration.
INBS expanded its market presence by adding 35 new accounts in the quarter, bringing its active customer base to over 450. The company continues to pursue international growth through strategic partnerships and multilingual system upgrades, indicating a commitment to global market expansion.
The company's technological innovation remains a key focus, with the recent securing of its sixth U.S. patent and ongoing regulatory efforts across key global markets. Its Intelligent Fingerprinting Drug Screening System, which enables rapid drug screening through fingerprint sweat analysis, potentially offers a transformative solution for workplace testing in industries such as construction, manufacturing, transport, and logistics.
The quarter's results suggest Intelligent Bio Solutions is making meaningful progress in establishing its non-invasive testing technology as a viable and potentially disruptive solution in medical diagnostics and workplace screening.
